Skip to main content

Drug Interactions between dabrafenib and ensartinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

dabrafenib ensartinib

Applies to: dabrafenib and ensartinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with moderate to potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of ensartinib, which is primarily metabolized via the isoenzyme in vitro. Clinical data characterizing the extent of this interaction and data with less potent inducers are not available.

MANAGEMENT: Concomitant use of ensartinib with moderate to potent inducers of CYP450 3A4 should generally be avoided. The possibility of diminished therapeutic effects should be considered. Consultation with package labeling and relevant institutional protocols may be advisable for further guidance.

Drug and food/lifestyle interactions

Moderate

dabrafenib food/lifestyle

Applies to: dabrafenib

Food may delay and reduce the absorption of dabrafenib, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take dabrafenib at least 1 hour before or 2 hours after a meal.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Multikinase inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:

  • dabrafenib
  • ensartinib

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer